Frequency and mutational spectrum of PIK3CA gene mutations in breast cancer patients: Largest and first report from Lebanon

Next-Generation Sequencing-Based Analysis of Clinical and Pathological Features of PIK3CA-Mutated Breast Cancer

“…Our study explores the clinicopathological landscape of breast cancer patients who possess the PIK3CA mutation. With a 41% prevalence of PIK3CA mutation in our sample, the findings align with other research, considering that the median prevalence of this mutation in breast cancer patients is estimated to be 36% [ 36 , 37 ]. Our data indicate that patients with PIK3CA mutations are diagnosed at an older age, with a median age at diagnosis of 64 years compared to 55 years for those without the alteration.…”

Liquid biopsies based on cell-free DNA as a potential biomarker in head and neck cancer

“…The ongoing advances in the detection and characterization of ctDNA have allowed the design of single- and multigene assays to detect genetic alterations in plasma cfDNA for using it as companion diagnostics and selecting molecular targeted therapies. In this line, various gene specific ctDNA tests are already being used into clinical practice for cancer management like the Cobas® EGFR mutation test V2 (Roche), that allows to screen for EGFR mutations in plasma cfDNA from patients with advanced- stage non-small cell lung cancer, and the Therascreen PIK3CA RGQ PCR kit (Qiagen), that is designed to detect PIK3CA mutations in tumor tissue or plasma from patients with advanced-stage hormone receptor (HR)+ /HER2 − breast cancer [95] . Additionally, high-throughput NGS-based multigene liquid biopsy tests have been approved by the FDA for comprehensive ctDNA testing such as the Guardant360 CDx (Guardant) and the FoundationOne Liquid CDx (F1LCDx), that allows a broad cancer genotyping and the identification of clinically actionable alterations that can guide the use of molecularly targeted therapies in different solid tumor entities [96] , [97] .…”